Home | Contact Us | Newsletter | Usersclub | Books | Audio Seminars

New Ordering of the Labcompliance Newsletter and/or Renewal to comply with the General Data Protection Regulation (GDPR)

Now you can get free update information on validation and compliance through an e-newsletter. Existing newsletter subscribers must renew the Newsletter to comply with the General Data Protection Regulation.


  • News from FDA and other agencies: regulations, guidance documents, inspection and enforcement practices
  • News from industry task forces and other organizations, like ICH, ISPE, and PDA.
  • Information and links to new literature for free  downloads from the Internet
  • New FDA warning letters, 483 inspectional observations and establishment inspection reports.
  • Information on new conferences and seminars related to FDA compliance
  • Update on new products and services from Labcompliance
  • Regular update on Labcompliance seminars

New Ordering or Renewal


I wish to receive the complimentary Labcompliance Newsletter  and

I read the Labcompliance
data protection policy and agree with the described handling and processing of personal data.

Title *
First Name*
Last Name *
Company * (if applicable)
Job Title *
Country *
Email *
Repeat E-Mail for Verification *

* Required Fields

Enter the code shown. Help


Author of the Labcompliance Newsletter

Dr. Ludwig Huber is the author of the Labcompliance Newsletter. He has been conducting over 300 web and audio or video based seminars since fifteen years. He is worldwide director for FDA compliance at Labcompliance.


Dr. Huber has published several books related to validation and compliance, for example: Validation of Computerized Analytical and Networked Systems. He was or still is a member of several committees, e.g., of the GAMP Special interest group (SIG) on Laboratory Computers, PDA Part 11 task force, IVT task force on network infrastructure qualification and the European Compliance Academy. He frequently visited FDA in Rockville, VA, and participated in panel discussions with FDA professionals. For more information, click here.